Ines Brueckmann
Holzkirchen, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Switchback from biosimilar tumor necrosis factor-alpha inhibitors to reference medicines: a review.
Journal: Expert review of clinical immunology
Published: September 03, 2026
Comparison of treatment with GP2017 (an adalimumab biosimilar) and reference adalimumab in people with plaque psoriasis: a plain language summary of the ADACCESS trial.
Journal: Immunotherapy
Published: February 19, 2026
Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summary.
Journal: Immunotherapy
Published: May 12, 2025
Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: May 05, 2025
Comparing anti-drug antibody signal-to-noise ratios to assess immunogenicity and interchangeability in adalimumab biosimilar studies.
Journal: Expert opinion on biological therapy
Published: November 15, 2024
Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOP.
Journal: Annals of hematology
Published: February 29, 2024
Patient Experience with the SensoReady® Autoinjector Pen versus a Comparator Device: Results from a Canadian Patient Survey in Rheumatoid Arthritis and Crohn´s Disease.
Journal: Patient preference and adherence
Published: January 19, 2024
Filgrastim biosimilar (EP2006): A review of 15 years' post-approval evidence.
Journal: Critical reviews in oncology/hematology
Published: December 18, 2023
Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study.
Journal: Advances in therapy
Published: June 22, 2023
Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: January 28, 2021
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: October 29, 2020
Showing 1-11 of 11
Last Updated: 09/26/2026